Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase III ENHANCE-2 Trial for COPD

Verona Pharma plc announced its top-line Phase III ENHANCE-2 (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) trial results evaluating nebulized ensifentrine for the maintenance treatment of COPD.